1 recruiting, 1 terminated. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
Follow PD(L)-1 inhibitor: new trials by email Literature Review of PD(L)-1 inhibitor trials Research Report on PD(L)-1 inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor - Thyroid Cancer, Thyroid Neoplasms | Recruiting | Fujian Medical University | 120 | 2025-12-23 | 2026-02-19 | |
| A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors ADA-011, PD(L)-1 inhibitor - Solid Tumor, Adult | Phase 1 | Terminated | Adanate, Inc | 46 | 2022-11-15 | 2025-01-28 |
Adanate, Inc (1) · Fujian Medical University (1)
China (1) · United States (1)